News & Analysis on Clinical Trial Services & Contract Research And Development
French firm Vivalis has announced the first data evaluating its proprietary EBx cell lines for the production of monoclonal antibodies (MAbs), with initial results suggesting high cytotoxic properties in the resultant MAbs.
Lab equipment specialist Sotax has announced the creation of a new contract research organisation (CRO) focused exclusively on dissolution testing services.
Nabi Biopharmaceuticals has announced the creation of the second of its two new business units, Nabi Pharmaceuticals, a month after spinning off its Biologics segment.
WuXi PharmaTech, the biggest Chinese contract research organisation (CRO), has put an end to weeks of speculation by officially announcing it plans an initial public offering (IPO) on the New York Stock Exchange.
Roche, Alexza Pharmaceuticals, WuXi PharmaTech, Ambrx and NovaDel Pharma have all had people on the move in the world of pharmaceutical manufacturing.
Biovail has this week sought to reassure its investors after the news that US regulators issued the company with a Non Approval letter for its new bupropion salt anti-depressant.
Cell Therapeutics has acquired oncology expert Systems Medicine (SMi) in a deal worth up to $35m (€25.5m) that includes worldwide rights to brostallicin that belongs to a new class of cancer drugs.
Australian biotech company, Benitec, is about to start dosing patients in the first ever human trial of its RNA therapy, which attacks HIV on three separate fronts.